Related Experiment Video
Updated: Aug 14, 2026
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Multilobated B-cell lymphoma. A clinicopathologic study of 24 cases
R L Weiss1, E R Ashwood, C R Kjeldsberg
1Department of Pathology, University of Utah School of Medicine, Salt Lake City 84132.
Insights
Multilobated B-cell lymphoma, a variant of non-Hodgkin's lymphoma, shows similar behavior to intermediate-grade, diffuse, large-cell types. This finding aids in understanding and managing this specific lymphoma subtype.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- This study examines the clinical, histologic, and immunologic characteristics of multilobated B-cell lymphoma.
- Focuses on cases where over 50% of tumor cells exhibit nuclear multilobation.
Observation:
- Analyzed 24 cases (13 males, 11 females; age 13-79).
- Predominantly node-based presentations observed.
- Seventeen patients (71%) had advanced stage (III or IV) disease.
Findings:
- Complete remission achieved in 59% of patients.
- 58% of patients were alive after follow-up (10-124 months).
- 1-year survival rate was 65%; relapse occurred in 31% of complete responders.
Implications:
- Multilobated B-cell lymphoma exhibits behavior comparable to intermediate-grade, diffuse, large-cell non-Hodgkin's lymphomas.
- Findings support current classification and treatment strategies for this lymphoma variant.
- Further research may refine prognostic indicators and therapeutic approaches.
Abstract:
The clinical, histologic, and immunologic features of 24 cases of multilobated B-cell lymphoma are presented and compared with those of previously reported cases. Cases were included in this study when more than 50% of the tumor cells had nuclear multilobation. There were 13 males and 11 females with an age range of 13 to 79 years. A slight predominance of node-based presentations was observed. Seventeen patients (71%) presented with advanced (stage III or IV) disease. Complete remissions were achieved in 13 (59%) of 22 patients, and 14 (58%) of the 24 patients were still alive after a follow-up period ranging from 10 to 124 months. The 1-year survival was 65% (SE = 10%). Relapses occurred in 4 (31%) of 13 patients with complete responses. These observations, together with those previously reported, support the conclusion that the multilobated B-cell variant of non-Hodgkin's lymphoma behaves in a fashion similar to that of the intermediate-grade, diffuse, large-cell non-Hodgkin's lymphomas.
